Epicept Corporation, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA.
Bioorg Med Chem Lett. 2010 Feb 1;20(3):1288-92. doi: 10.1016/j.bmcl.2009.11.025. Epub 2009 Nov 12.
As a continuation of our studies of apoptosis inducing 9-oxo-9H-fluorene-1-carboxamides as potential anticancer agents, we explored modification of the 9-oxo-9H-fluorene ring. SAR studies showed that most changes to the 9-oxo-9H-fluorene ring were not well tolerated, except the 9H-fluorene (2b) and dibenzothiophene (2d) analogs, which were about twofold less active than the 9-oxo-9H-fluorene analog 2a. Significantly, introduction of substitutions at the 7-position of the 9-oxo-9H-fluorene ring led to compounds 5a-5c with improved activity. Compound 5a was found to have EC(50) values of 0.15-0.29 microM against T47D, HCT116, and SNU398 cells, about fivefold more potent than the original lead 2a. As opposed to the original lead compound 2a, compounds 5a-5b were active in a tubulin inhibition assay, indicating a change of mechanism of action. The potent azido analog 5c could be utilized for target identification.
作为我们对具有潜在抗癌活性的 9-氧代-9H-芴-1-甲酰胺诱导细胞凋亡的研究的延续,我们探索了对 9-氧代-9H-芴环进行修饰。SAR 研究表明,除了 9H-芴(2b)和二苯并噻吩(2d)类似物之外,9-氧代-9H-芴环的大多数变化都不能很好地耐受,而 9-氧代-9H-芴类似物 2a 的活性约低两倍。值得注意的是,在 9-氧代-9H-芴环的 7 位引入取代基可得到活性提高的化合物 5a-5c。发现化合物 5a 对 T47D、HCT116 和 SNU398 细胞的 EC50 值为 0.15-0.29 μM,比原始先导化合物 2a 强约五倍。与原始先导化合物 2a 相反,化合物 5a-5b 在微管蛋白抑制测定中具有活性,表明作用机制发生了变化。具有强效叠氮基的类似物 5c 可用于靶标鉴定。